Amgen’s Biosimilars Business Dips As Key Contributors Face Fresh Competition

Company Remains Confident That Future Launches Will See It Meet Ambitious Targets

 
• By Chloe Kent
  
Amgen logo next to syringe
Amgen expects to launch another six biosimilars by the end of the decade. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business